Tranexamic Acid in Civilian Trauma Care in the California Prehospital Antifibrinolytic Therapy Study

Michael M. Neeki, DO, MS; Fanglong Dong, PhD; Jake Toy, BA; Reza Vaezazizi, MD; Joe Powell, EMT-P; David Wong, MD; Michael Mousselli, BS; Massoud Rabiei, BS; Alex Jabourian, DO; Nichole Niknafs, DO; Michelle Burgett-Moreno, BA; Richard Vara, RN, BSN; Shanna Kissel, RN, MSN; Xian Luo-Owen, MD, PhD; Karen R. O'Bosky, MD; Daniel Ludi, MD; Karl Sporer, MD; Troy Pennington, DO; Tommy Lee, MD; Rodney Borger, MD; Eugene Kwong, MD

Disclosures

Western J Emerg Med. 2018;19(6):977-986. 

In This Article

Conclusion

The current study noted reduced mortality at 28 days following the administration of prehospital TXA in patients with signs of traumatic hemorrhagic shock. We further noted a decrease in blood product transfused and shorter hospital and ICU LOS, without an increase in thromboembolic events. Finally, this study demonstrated that TXA can be effectively and feasibly administered by civilian prehospital providers and in accordance with North American emergency medicine standards. Our findings support the use of prehospital TXA in adult civilian traumatic injury with signs of hemorrhagic shock.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....